Remission From Stage D Heart Failure

Phase 4 Unknown 40 enrolled University of Louisville Thoratec Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function after undergoing a standardized Left Ventricular Assist Device (LVAD) plus pharmacologic recovery treatment and testing protocol to allow removal of the LVAD within 18 months.

Timeline

Start: 2013-01
Primary completion: 2017-12
Completion: 2017-12

Publications

Birks EJ, Drakos SG, Patel SR, Lowes BD, Selzman CH, Starling RC, Trivedi J, Slaughter MS, Alturi P, Goldstein D, Maybaum S, Um JY, Margulies KB, Stehlik J, Cunningham C, Farrar DJ, Rame JE. Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results. Circulation. 2020 Nov 24;142(21):2016-2028. doi: 10.1161/CIRCULATIONAHA.120.046415. Epub 2020 Oct 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Carvedilol	Other / unclassified	25 mg	—
Background	Digoxin	Other / unclassified	125 g	—
Background	LISINOPRIL ANHYDROUS	Small molecule	40 mg	—
Background	Losartan	Other / unclassified	150 mg	—
Background	Spironolactone	Small molecule	25 mg	—

Remission From Stage D Heart Failure

Summary

Timeline

Publications

Drugs

Indications